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Abstract
Background: Gastrointestinal stromal tumors (GIST) recently have been recognized as a genetically and biologically
heterogeneous disease. In addition to KIT or PDGFRA mutated GIST, mutational inactivation of succinate
dehydrogenase (SDH) subunits has been detected in the KIT/PDGFRA wild-type subgroup, referred to as SDH
deficient (dSDH). Even though most dSDH GIST harbor mutations in SDHx subunit genes, some are SDHx wild type.
Epigenetic regulation by DNA methylation of CpG islands recently has been found to be an alternative mechanism
underlying the lack of SDH complex in GIST.
Case presentation: We report a particular case of dSDH GIST, previously analyzed with microarrays and next-generation
sequencing, for which no molecular pathogenetic events have been identified. Gene expression analysis showed
remarkable down-modulation of SDHC mRNA with respect to all other GIST samples, both SDHA-mutant and KIT/
PDGFRA-mutant GIST. By a bisulfite methylation assay targeted to 2 SDHC CpG islands, we detected hypermethylation
of the SDHC promoter.
Conclusion: Herein we report an additional case of dSDH GIST without SDHx mutation but harboring hypermethylation
in the SDHC promoter, thus confirming the complexity of the molecular background of this subtype of GIST.
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Background
Gastrointestinal stromal tumors (GIST) recently have
been recognized as a genetically and biologically hete-
rogeneous disease [1]. In addition to KIT- or PDGFRA-
mutated GIST, mutational inactivation of succinate de-
hydrogenase (SDH) subunits has been detected in the
KIT/PDGFRA wild-type subgroup. This latter type of
GIST can be identified by negative staining of SDHB pro-
teins and is defined as SDH-deficient (dSDH) GIST [2, 3].
Epigenetic regulation by DNA methylation of CpG
islands has been shown to play a relevant role in the
pathogenesis of several cancers. The hypermethylation
phenotype has been detected in dSDH GIST, and more
recently evidence of the involvement of methylation of
SDHC in this subgroup has been reported [4–7].
Herein we reported the molecular characterization of 1
case of dSDH GIST—analyzed with microarrays, next-
generation sequencing, and bisulfite sequencing—identify-
ing, as unique molecular pathogenic event, methylation of
the SDHC promoter.
Case presentation
A 25-year-old woman had multifocal, epithelioid gastric
GIST (CARE checklist is available as Additional file 1). KIT
(exons 9, 11, 13, and 17) and PDGFRA (exons 12, 14, and
18) molecular analysis did not show evidence of mutations.
The clinical/pathological features matched well with those
describing dSDH GIST (female sex, young age, and multi-
focal and epithelioid gastric GIST). Moreover, in a gene
expression analysis previously reported (GSE20710), we
showed that the expression profile of this tumor (GIST_21)
was similar to the profile of 3 patients (GIST_07, GIST_10,
and GIST_24) who we subsequently identified as having
mutated SDHA [3, 8]. To better characterize GIST_21, all
SDHx subunits were sequenced by the Sanger method, but
the analysis did not show any mutations.
To search for alterations that might not have been de-
tected by Sanger sequencing, we performed paired-end
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whole exome sequencing of GIST_21 (see Additional file
2 for materials and methods), without finding any muta-
tions in any SDHx coding sequences or flanking intronic
regions. Exhaustive exome sequencing analysis revealed
no pathogenic mutations in other GIST-related genes,
such PDGFRA, BRAF, and neurofibromin 1, and only a
nonsynonymous missense variant in exon 18 of KIT.
This variant is described in the COSMIC database
(COSM133780) in 1 case of malignant melanoma. Be-
cause the matched normal sample for this patient was
not available, we were not able to determine if this KIT
variant was somatic or germinal.
By gene expression analysis, we examined the expres-
sion levels of the 4 subunits of the SDH complex; as
shown in Fig. 1a, we detected a remarkable down-
modulation of SDHC mRNA in GIST_21 with respect to
all other GIST samples, both SDHA-mutant and KIT/
PDGFRA-mutant GIST. Moreover, Western blot im-
munoassay showed that GIST_21 had normal SDHA but
markedly decreased SDHB protein expression (Fig. 1b)
and would be predicted to have a loss of SDH complex
activity. Additionally, SNP6.0 genotyping on GIST_21
showed a normal karyotype, with no detectable loss of
heterozygosity or chromosome 1q deletion [9].
Hypermethylation of the SDHC promoter region was
recently associated with Carney triad–related GIST and
dSDH GIST without SDHx mutation [6, 7]. Thus, we
designed a bisulfite methylation assay to look for potential
epimutations in the 2 known CpG islands of the SDHC
promoter regions, CpG17 and CpG27. This analysis was
performed in 4 dSDH (including GIST_21 and 3 GIST
without SDHx mutations) and in 8 KIT/PDGFRA-mu-
tated GIST. Hypermethylation of the SDHC promoter was
found only in GIST_21, and this alteration was detected
in heterozygosis at all CpG sites (Fig. 1c). The methylated
case showed a significant 0.63-fold decrease in SDHC
mRNA expression level (P = 0.0001) in comparison with
the 11 methylation-negative cases (Fig. 1d).
Discussion
Previous studies showed that all dSDH GIST are charac-
terized by a genome-wide hypermethylation phenotype,
but the downregulation of the SDH complex remains
unexplained for those cases lacking mutations in the
Fig. 1 SDHC alteration of GIST_21. a Down-modulation of SDHC mRNA in GIST_21 (red) with respect to the other SDHA-mutated (orange) and KIT/
PDGFRA-mutated (light blue) GIST. b Western blot immunostaining of SDHA and SDHB proteins. GIST_21 showed negative SDHB staining
similar to SDHA-mutant GIST. Actin was used as loading control. c Partial chromatogram of PCR products of the promoter region of the SDHC
gene. Tumor genomic DNA from GIST_21 and 11 GIST control samples (3 SDHA and 8 KIT/PDGFRA mutants) were treated with bisulfite before
amplification and sequencing. The upper sequence, belonging to GIST_21, carries methylated CpG in heterozygous status, whereas the lower
sequence is an example of methylation-negative control samples. Stars show the location of CpG dinucleotides methylated in the predicted CpG
island, while boxes show the C outside of the CpG island completely converted by bisulfite to T. d SDHC mRNA expression level comparison
between the methylated case (GIST_21) and the 11 methylation-negative samples (3 SDHA and 8 KIT/PDGFRA mutants). P value was estimated
with one sample t test
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SDHx subunits. The case of dSDH GIST that we report
here has not shown any molecular alterations in the
SDHx complex nor have other pathogenetic events been
detected by whole exome sequencing. Epigenetic modifi-
cation of the SDHC promoter was the only pathogenetic
event identified. Haller et al. [6] reported for the first
time the presence of aberrant DNA methylation of the
SDHC promoter in 4 patients with dSDH Carney triad–
related GIST that are known to lack SDHx mutations.
More recently, Killian et al. [7] performed a genome-
wide methylation assay on 59 cases of dSDH GIST,
selected on the basis of SDHB-negative immunostaining.
They detected recurrent hypermethylation of the SDHC
promoter in 94 % (15 of 16 cases) of the SDHx wild-type
subgroup (ie, deficiency of the SDHB protein but no
mutations in the coding region of any SDH subunits).
This event was not confirmed outside of the SDHC pro-
moter, in which there was no significant hypermethyla-
tion. In our cohort, SDHC epimutation was not detected
in either SDHx- or KIT/PDGFRA-mutated GIST. This
finding is consistent with those of previous reports [6, 7],
in which SDHC hypermethylation was found only in
dSDH GIST without SDHx mutation. Moreover, Killian
et al. [7] found that the SDHC methylation was mutually
exclusive of mutations or loss of heterozygosity events in
other SDHx subunits, with the exception of hemimethyla-
tion that was associated with heterozygous mutations of
the SDHC gene (4 of 7 cases). In particular, the authors
found 4 cases with monoallelic methylation of SDHC in
compound heterozygosity with mutation of SDHC,
consistent with the Knudson 2-hit model, whereas 3 cases
were negative for any other alterations. The case we
reported, GIST_21, could be part of this latter group, also
confirming that the detection of partial methylation of
SDHC could be a marker of the complete disassembly of
the SDH complex through the down-modulation of SDHC
and the consequent degradation of the SDHB protein.
The presence of additional undetected mutations or
INDELs in SDHC was not likely because the Exome
sequencing probes also covered the proximal SDHC pro-
moter region and the single-nucleotide polymorphism
array did not detect any copy number alterations. Other-
wise, due to technical limitations of the sequencing tech-
nologies, we could not exclude the presence of other
alterations in SDHC or other SDHx subunits that could
lead to the complete absence of the SDHB protein (e.g.,
a mutation in a region not sufficiently covered by exome
capture or a cryptic deletion inside the SDHC gene).
However, considering the rarity and complexity of these
molecular events, the clinical implications of these
differences in SDH complex deregulation are still not
completely known but probably are not associated with
a different clinical profile and different behavior among
the dSDH GIST cases.
Conclusion
In conclusion, herein we reported an additional case of
dSDH GIST without SDHx mutation, but harboring
hypermethylation in the SDHC promoter, thus confirming
the relevance of an epigenomic event in this pathology.
For this patient, no other molecular pathogenic event was
detected. Our case may confirm the complexity of the
molecular background of dSDH GIST by the integration
of genomic and epigenomic assays using high-throughput
technologies that helped to identify the specific mechan-
ism of SDH complex inactivation underlying the loss of
SDHB protein expression not driven by SDHx mutations
in this subgroup of GIST.
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